Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.28)
# 940
Out of 5,182 analysts
68
Total ratings
53.19%
Success rate
14.37%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Neutral | $100 → $105 | $86.68 | +21.14% | 5 | Feb 3, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $14.27 | +40.15% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $73.93 | +2.80% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $7.96 | +75.88% | 1 | Aug 4, 2025 | |
| ILMN Illumina | Maintains: Neutral | $85 → $100 | $135.78 | -26.35% | 1 | Aug 1, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $18.47 | +67.84% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $22.43 | -59.88% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $60.40 | -45.36% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $117.20 | +62.12% | 6 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $26.33 | -27.84% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $380 → $390 | $307.12 | +26.99% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $55.00 | - | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $87.60 | -37.21% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $114.52 | +39.71% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $469.21 | +42.79% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $4.80 | +316.67% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,267.07 | +10.49% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.60 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $36.79 | +144.63% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $175.15 | +54.15% | 4 | Dec 20, 2023 |
Revvity
Feb 3, 2026
Maintains: Neutral
Price Target: $100 → $105
Current: $86.68
Upside: +21.14%
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $14.27
Upside: +40.15%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $73.93
Upside: +2.80%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $7.96
Upside: +75.88%
Illumina
Aug 1, 2025
Maintains: Neutral
Price Target: $85 → $100
Current: $135.78
Upside: -26.35%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $18.47
Upside: +67.84%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $22.43
Upside: -59.88%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $60.40
Upside: -45.36%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $117.20
Upside: +62.12%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $26.33
Upside: -27.84%
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $307.12
Upside: +26.99%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $55.00
Upside: -
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $87.60
Upside: -37.21%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $114.52
Upside: +39.71%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $469.21
Upside: +42.79%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $4.80
Upside: +316.67%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,267.07
Upside: +10.49%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.60
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $36.79
Upside: +144.63%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $175.15
Upside: +54.15%